제이에스링크

127120KOSDAQ자연과학 및 공학 연구개발업

51.3 / 100

Reference Date: 2026-06-10

Financial Score10.0 / 40

News Sentiment21.3 / 25

Momentum8.0 / 20

Disclosure12.0 / 15

AI Analysis: PBR raises overvaluation concerns, Operating Profit is on a declining trend. Plunged 16.0% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

JS Link operates in genomics analysis, personalized medicine, and diagnostics, leveraging advancements in genomic technology and rising demand for customized treatments. As genome sequencing costs have drastically decreased and bioinformatics becomes crucial for handling large data, the molecular diagnostics market is rapidly expanding. Establishing Asia-specific genomic databases is key to securing global competitiveness.

Number of Employees

139people

Average Salary

53.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 62.704.0Point

PBR

17.44Industry Average 3.240.0Point

5.4x industry avg (risky)

ROE

-35.13Industry Average -32.093.5Point

In line with industry avg

Debt Ratio

9.28Industry Average 7.312.0Point

Higher than industry avg (caution)

Trend 2023~20250.5 / 10 points

Revenue Growth Rate

0.5 / 3

Avg ▼3.0% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼73.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -32.6% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 85

Positive
유전체 분석 1세대 마크로젠, 해외 매출 62% 달성…AI 대전환 속도
마크로젠의 유전체 분석 기술 기반 AI 활용 확장으로 인해 제이에스링크 관련 긍정적인 시장 반응 예상.
Positive
제이에스링크, 24.9억 규모 공급계약 체결
제이에스링크는 질병관리청과의 대규모 염기서열 정보 생산 계약 체결로 인해 긍정적인 재무 성과를 기대할 수 있다.

Detailed Momentum

52-week position6.0Point

52w upper range (63%)

Current 34,550Won52-week high 48,90052-week low 9,140

1-month return0.0Point

1m -16.04% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

4 totalPositive 1Neutral 3Negative 0

Neutral분기보고서 (2026.03)2026-05-15
Positive단일판매ㆍ공급계약체결2026-05-13
Neutral주요사항보고서(전환사채권발행결정)2026-05-13
Neutral주요사항보고서(전환사채권발행결정)2026-05-13